Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
Explore this paper's citation graph
Summary
A 69-year-old never-smoking Japanese woman with postoperative recurrent lung adenocarcinoma retreated with osimertinib after osimERTinib-induced pneumonitis, suggesting osimerinib rechallenge after oSimertinIB-induced pneumoniaonitis may be an option, with limited alternative therapeutic options.
- Type
- article
- Published
- 2017-12-11
- Cited by
- 27
- References
- 20
- Access
- Open access
- OpenAlex
- https://openalex.org/W2772985786
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3652441
Keywords
Osimertinib, Medicine, Pneumonitis, Interstitial pneumonitis, Lung cancer
References
- Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
- Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
- Recurrent gefitinib-induced interstitial lung disease.
- Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
- Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease
- Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
- Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
- Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
- Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
- Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
- Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report
- Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report.
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
- Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease
- Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
- Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
- Retreatment With Osimertinib Following Pneumonitis
- Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
Cited by
- Retreatment With Osimertinib Following Pneumonitis
- Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
- Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease
- Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
- Late-onset severe pneumonitis under osimertinib.
- Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature
- Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study
- Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
- Pulmonary toxicity of systemic lung cancer therapy
- Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma
- Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
- Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
- Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
- EGFR突变非小细胞肺癌患者奥希替尼诱导间质性肺疾病后奥希替尼再挑战：病例报道
- Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients
- Nodule‐type pneumonitis mimicking lung abscess or tumor recurrence on chest computed tomography identified as osimertinib‐induced pneumonitis: A case report
- TAPO in first‐line osimertinib therapy and continuation of osimertinib
- Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
- Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
- Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
Related papers
- Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
- Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
- Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
- P2.09-20 Updated Data of Osimertinib Rechallenge after Pneumonitis; A Multicenter Retrospective Cohort Study
- Interstitial pneumonitis.
- [A case of AIDS patient who was hard to diagnose from an initial symptom of interstitial pneumonitis].
- Interstitial pneumonitis associated with infliximab therapy.
- [A case of pneumonitis induced by Bofu-tsusho-san].
- EP10.01-13 Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice.